472 related articles for article (PubMed ID: 31246976)
1. Role of HDL function and LDL atherogenicity on cardiovascular risk: A comprehensive examination.
Hernáez Á; Soria-Florido MT; Schröder H; Ros E; Pintó X; Estruch R; Salas-Salvadó J; Corella D; Arós F; Serra-Majem L; Martínez-González MÁ; Fiol M; Lapetra J; Elosua R; Lamuela-Raventós RM; Fitó M
PLoS One; 2019; 14(6):e0218533. PubMed ID: 31246976
[TBL] [Abstract][Full Text] [Related]
2. Apolipoprotein B and non-high-density lipoprotein cholesterol reveal a high atherogenicity in individuals with type 2 diabetes and controlled low-density lipoprotein-cholesterol.
Fonseca L; Paredes S; Ramos H; Oliveira JC; Palma I
Lipids Health Dis; 2020 Jun; 19(1):127. PubMed ID: 32505210
[TBL] [Abstract][Full Text] [Related]
3. [Diabetic dyslipidaemia and the atherosclerosis].
Márk L; Dani G
Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
[TBL] [Abstract][Full Text] [Related]
4. Low-density lipoprotein cholesterol-to-apolipoprotein B ratio as a potential indicator of LDL particle size and plasma atherogenicity in type 2 diabetes.
Viktorinova A; Malickova D; Svitekova K; Choudhury S; Krizko M
Diabetes Res Clin Pract; 2021 Jun; 176():108858. PubMed ID: 34015391
[TBL] [Abstract][Full Text] [Related]
5. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Nesto RW
Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
[TBL] [Abstract][Full Text] [Related]
6. Circulating PCSK9 levels are positively correlated with NMR-assessed atherogenic dyslipidaemia in patients with high cardiovascular risk.
Guardiola M; Plana N; Ibarretxe D; Cabré A; González M; Ribalta J; Masana L
Clin Sci (Lond); 2015 Jun; 128(12):877-82. PubMed ID: 25649668
[TBL] [Abstract][Full Text] [Related]
7. Effect of Extended-Release Niacin on High-Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin-Treated Patients.
Yadav R; Liu Y; Kwok S; Hama S; France M; Eatough R; Pemberton P; Schofield J; Siahmansur TJ; Malik R; Ammori BA; Issa B; Younis N; Donn R; Stevens A; Durrington P; Soran H
J Am Heart Assoc; 2015 Sep; 4(9):e001508. PubMed ID: 26374297
[TBL] [Abstract][Full Text] [Related]
8. HDL subfractions analysis: a new laboratory diagnostic assay for patients with cardiovascular diseases and dyslipoproteinemia.
Oravec S; Dostal E; Dukát A; Gavorník P; Kucera M; Gruber K
Neuro Endocrinol Lett; 2011; 32(4):502-9. PubMed ID: 21876506
[TBL] [Abstract][Full Text] [Related]
9. Association of Lipoproteins, Insulin Resistance, and Rosuvastatin With Incident Type 2 Diabetes Mellitus : Secondary Analysis of a Randomized Clinical Trial.
Dugani SB; Akinkuolie AO; Paynter N; Glynn RJ; Ridker PM; Mora S
JAMA Cardiol; 2016 May; 1(2):136-45. PubMed ID: 27347563
[TBL] [Abstract][Full Text] [Related]
10. Pattern of dyslipidemia and evaluation of non-HDL cholesterol as a marker of risk factor for cardiovascular disease in type 2 diabetes mellitus.
Pandeya A; Sharma M; Regmi P; Basukala A; Lamsal M
Nepal Med Coll J; 2012 Dec; 14(4):278-82. PubMed ID: 24579534
[TBL] [Abstract][Full Text] [Related]
11. Circulating non-HDL-C levels were more relevant to atherogenic lipoprotein subfractions compared with LDL-C in patients with stable coronary artery disease.
Zhu CG; Zhang Y; Xu RX; Li S; Wu NQ; Guo YL; Sun J; Li JJ
J Clin Lipidol; 2015; 9(6):794-800. PubMed ID: 26687700
[TBL] [Abstract][Full Text] [Related]
12. Would Janus' view on HDL be useful?
Kasko M; Kasko V; Oravec S
Bratisl Lek Listy; 2018; 119(4):245-248. PubMed ID: 29663823
[TBL] [Abstract][Full Text] [Related]
13. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T
Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548
[TBL] [Abstract][Full Text] [Related]
14. Oxidized low-density lipoprotein is negatively correlated with lecithin-cholesterol acyltransferase activity in type 2 diabetes mellitus.
Nakhjavani M; Asgharani F; Khalilzadeh O; Esteghamati A; Ghaneei A; Morteza A; Anvari M
Am J Med Sci; 2011 Feb; 341(2):92-5. PubMed ID: 20890173
[TBL] [Abstract][Full Text] [Related]
15. Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment.
Carr SS; Hooper AJ; Sullivan DR; Burnett JR
Pathology; 2019 Feb; 51(2):148-154. PubMed ID: 30595507
[TBL] [Abstract][Full Text] [Related]
16. Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels.
Querton L; Buysschaert M; Hermans MP
J Clin Lipidol; 2012; 6(5):434-42. PubMed ID: 23009779
[TBL] [Abstract][Full Text] [Related]
17. Effect of three consecutive meals on the physicochemical properties of HDL and LDL in individuals with the metabolic syndrome and patients with type 2 diabetes.
Scheffer PG; Tushuizen ME; Vermue HP; Schindhelm RK; Rustemeijer C; Diamant M
Eur J Clin Nutr; 2011 Nov; 65(11):1242-9. PubMed ID: 21712838
[TBL] [Abstract][Full Text] [Related]
18. Decreased cholesterol efflux capacity and atherogenic lipid profile in young women with PCOS.
Roe A; Hillman J; Butts S; Smith M; Rader D; Playford M; Mehta NN; Dokras A
J Clin Endocrinol Metab; 2014 May; 99(5):E841-7. PubMed ID: 24512495
[TBL] [Abstract][Full Text] [Related]
19. Diabetic dyslipidemia.
Kreisberg RA
Am J Cardiol; 1998 Dec; 82(12A):67U-73U; discussion 85U-86U. PubMed ID: 9915665
[TBL] [Abstract][Full Text] [Related]
20. Women have a larger and less atherogenic low density lipoprotein particle size than men.
Nikkilä M; Pitkäjärvi T; Koivula T; Solakivi T; Lehtimäki T; Laippala P; Jokela H; Lehtomäki E; Seppä K; Sillanaukee P
Atherosclerosis; 1996 Jan; 119(2):181-90. PubMed ID: 8808495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
